In contrast, studies have demonstrated that moderate reduction of mTOR activity by ~25%–30% consistently improves aspects of brain function in models of aging (Halloran et al., 2012) and of age‐associated neurological disease (Jahrling et al., 2018; Lin et al., 2017, 2013; Van Skike et al., 2018). This evidence concerns the gene MTOR and nervous system disorder.